Align Technology (ALGN) Projected to Post Earnings on Wednesday

Align Technology (NASDAQ:ALGN) is projected to announce its Q4 2025 results after the market closes on Wednesday, February 4th. Analysts expect the company to announce earnings of $2.99 per share and revenue of $1.0318 billion for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

Align Technology Stock Performance

Shares of NASDAQ ALGN opened at $163.03 on Monday. The firm has a market capitalization of $11.70 billion, a PE ratio of 31.60, a price-to-earnings-growth ratio of 1.83 and a beta of 1.84. Align Technology has a fifty-two week low of $122.00 and a fifty-two week high of $232.20. The stock’s 50-day simple moving average is $161.01 and its 200-day simple moving average is $148.94.

Institutional Investors Weigh In On Align Technology

A number of institutional investors have recently added to or reduced their stakes in ALGN. CYBER HORNET ETFs LLC acquired a new position in Align Technology during the second quarter valued at approximately $36,000. MUFG Securities EMEA plc acquired a new position in shares of Align Technology in the second quarter worth about $38,000. Caitong International Asset Management Co. Ltd raised its position in shares of Align Technology by 1,773.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 281 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 266 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Align Technology by 55.7% in the second quarter. EverSource Wealth Advisors LLC now owns 531 shares of the medical equipment provider’s stock worth $101,000 after buying an additional 190 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Align Technology by 16.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 726 shares of the medical equipment provider’s stock worth $137,000 after purchasing an additional 104 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ALGN. Morgan Stanley upped their price objective on shares of Align Technology from $142.00 to $154.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Jefferies Financial Group increased their price target on Align Technology from $140.00 to $155.00 in a report on Thursday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Align Technology in a report on Thursday, October 30th. Leerink Partners boosted their target price on shares of Align Technology from $189.00 to $210.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company lowered their price target on Align Technology from $199.00 to $181.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Six investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Align Technology has a consensus rating of “Hold” and an average price target of $176.82.

About Align Technology

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.